Abstract: Administration regimens suitable for vaccine compositions comprising polynucleotides encoding immunogenic polypeptides. Such administration regimens involve the repeated administration of a vaccine composition.

Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve, the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.

Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).

Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.

Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.

Abstract: The present invention concerns the use of PPAR? agonists in methods and compositions for the treatment or prevention of infection by hepatitis C virus (HCV) in mammals, especially humans.

Abstract: The present invention features methods of screening for compounds that inhibit HCV binding to a cell, methods of inhibiting IICV entry into a cell, and methods of actively or prophylactically treating against an IICV infection. The different methods are based on the identification of the scavenger receptor class B type I as a target site for HCV E2 binding to a cell.